Products
Vamikibart Biosimilar Monoclonal Antibody (IL-6) for Research
Cat No.: GMP-Bios-INN-1445
Anti-IL6 therapeutic antibody (Pre-made Vamikibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Vamikibart (development codes RG-6179/RO-7200220) is a humanized monoclonal antibody targeting interleukin-6 (IL6). It is developed by Roche for Retinal oedema, Diabetic macular oedema in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1445-1mg | 1mg | 3090 |
| GMP-Bios-INN-1445-10mg | 10mg | |
| GMP-Bios-INN-1445-100mg | 100mg | |
| GMP-Bios-INN-1445-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Vamikibart biosimilar, Whole mAb, Anti-IL6 Antibody: Anti-BSF-2/BSF2/CDF/HGF therapeutic antibody |
| INN Name | Vamikibart |
| Target | IL6 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Roche |
| Conditions Approved | na |
| Conditions Active | Retinal oedema;Diabetic macular oedema |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
